Chiglitazar - Chipscreen Biosciences
Alternative Names: Bilopine/Bilessglu; Carfloglitazar - Chipscreen Biosciences; Carfloglitazar sodium - Chipscreen Biosciences; Chiglitazar sodium - Chipscreen Biosciences; CS-038Latest Information Update: 24 Jul 2024
At a glance
- Originator Chipscreen Biosciences
- Class Aniline compounds; Antidementias; Antihyperglycaemics; Carbazoles; Fluorobenzenes; Hepatoprotectants; Phenyl ethers; Propionic acids; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Phase II Non-alcoholic steatohepatitis
- Discontinued Parkinson's disease
Most Recent Events
- 19 Jul 2024 Registered for Type 2 diabetes mellitus (Combination therapy) in China (PO)
- 18 Mar 2024 Chipscreen Biosciences completes a phase II clinical trial for Non-alcoholic steatohepatitis in China (NCT05193916)
- 18 Mar 2024 Efficacy and adverse event data from a phase II trial in Non-alcoholic steatohepatitis released by Chipscreen Biosciences